Overview

A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Status:
Withdrawn

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

This is a research study of a radiation treatment called stereotactic body radiotherapy (SBRT) plus a medicine called sorafenib. The purpose of this study is to evaluate the safety of SBRT plus Sorafenib to see what effects (good and bad) it has on the treatment of liver cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Indiana University

Treatments:

Niacinamide
Sorafenib